Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
EMA Top 5 - we're picked from 5 treatments on the rolling review list but further along than SNG. Mostly MABs some of which the FDA have already stopped using in the US due to variants. Top 10 to come.
Camostat has officially failed Activ2 due to futility - this was confirmed in a release on the 24th.
Activ2 Protocol update for non-infused agents is due.
Sprinter Trial ongoing and running in multiple countries.
H2 starts tomorrow....
It was changed to H2 therefore it will take longer, august/september best case, unless they will release uk arm first, pretty sure that will be ready in July
RM aka The boss..said H2, so anytime from tomorrow......best of luck to all the SNG rocket riders
Jez2 “ Are we still expecting the "big news" this week as heavily pushed by members of reddit group over the weekend?”
Wondering the same, fingers crossed
Lolades78, thanks for coming, lol!
Andrew, I've explained my post on the Argo forum and how is it very different from what you accuse me of.
I see by your messages that you seem fustrated and I think that fustration is clouding your judgement.
I haven't lied in any of my messages on this board. Out of respect for the other members on this board I'll leave this conversation here as it is an unnecessary distraction that you have brought up out of thin air.
Lolades78, are you suggesting it is acceptable to "resort to personal messages of this perticular tone" when it suits you? You do understand what a hypocrite is don't you?
As I posted, it was a virtual copy and paste of your message.
I see you have previously been accused of trolling this board but I've no idea what your motive is for posting here this time. As for "letting your emotions run a little wild here" you have decided you are being called a liar just because I copied a post of yours.
Sng just need to continue as they have and in the same professional manner as shortly a major will remove them from the market.
Discussion already underway IMO.
Gla
I didn't downtalk or lie about Synairgen in any way with my post. My response to the person on the Argo forum was because of a lie they had repeated. Would you perhaps that I had lied and said Synairgen were included in the 5 EU therapeutics?
I think you are letting your emotions run a little wild here. And I think the hypocrite comment is uncalled for as I have not done anything to earn that. I was an early investor here and still wish the company the best despite my reduction.
It was a virtual copy and paste of your post on the arb board, hence the miss post.
By the way I have a particular low opinion of hypocrites.
Andrewpcapp, I was replying to s120896 regarding the EU therapeutics and referencing the original poster. I think I'm allowed to do that. I fail to see the need for you to post this and comment on my investments which you know nothing about. I also don't understand the need for you to resort to personal messages of this perticular tone. I think a little civility would go a long way on these boards. To ease you mind my investments are doing very well and I hope the same for you.
Are we still expecting the "big news" this week as heavily pushed by members of reddit group over the weekend?
Lolades78, it looks like this was discussed yesterday? Besides s120896 had already posted 'we will fall into the other 5.....'
I find it somewhat strange that you continue to hang around this forum when weeks ago you sold 90% and suggested you'd be selling out completely. It is always tough selling out and missing a decent rise particularly when your other investments have tanked but there's always other opportunities to put mistakes right.
Good luck.
Ahh thanks. As expected SNG001 wasn't going to mentioned as one of these 5 promising treatments since they are not part of the rolling review undertaken atm. We are much more likely to be selected as the other treatments that they hope to start rolling reviews before year end.
s120896, see xviolet's post, the 5 were chosen by the EU yesterday.
"Jun 29 (Reuters) – The European Commission on Tuesday chose four antibody treatments and a rheumatoid arthritis drug re-targeted by Eli Lilly for an initial portfolio of preferred drugs to treat COVID-19 disease.
The drug selection is part of the EU Strategy on COVID-19 Therapeutics, launched in May, to accelerate EU approval and for a joint procurement plan on behalf of Member States, complementing more advanced efforts in vaccines matter.
The Commission’s selection of most promising treatments includes Eli Lilly and Incyte’s Olumiant for hospitalized COVID-19 patients receiving oxygen, as well as new antibody drugs for early-stage disease developed by Regeneron, Eli Lilly, Celltrion and an alliance of GlaxoSmithKline and its partner Vir."
So there are currently 4 Covid Treatments currently under rolling review at EMA;
Bamlanivimab and etesevimab
Regdanvimab
REGN-COV2 (casirivimab / imdevimab)
Sotrovimab
We have been told they wish to name 5 of the most promising treatments so you expect 4 will be the above. Could SNG001 be the other one? My bet it's more likely we will fall into the other 5 they wish to start the rolling reviews for year end as this will match with our P3 trial data. We should find out 1st July.
www.ema.europa.eu/en/events/ema-regular-press-briefing-covid-19-1
Really wish this BB has a way of pinning important messages to the top.
Instead I have to do it the manual way and have copied both Doc's and Pmjh's last comments onto my SNG folder!
Wedding anniversary? I usually forget mine LOL
It's only a hunch but i have a strong feeling something may drop on Monday as it's 28th June. That date stuck in my head months back but for the life of me I can't recall where I saw it. Anyway, neither here nor there but exhilarating days ahead...
In the near future, we have two events to look forward to:
1) Imminent inclusion into the EMA list of approved drugs ('Imminent' as defined by RM ;-) - and s12, I hear what you say. This could happen later in the year, absolutely fantastic if this happens sooner.
2) However, don't forget that we are also waiting on Activ2 news i.e. that we move to phase 3 and with that, application for an EUA and pre-order from the US government.
Pmjh I would love it if you're correct. I just think October for approval is to early. I think we are much more likely to be one of the other 7 treatments they want to include for Rolling reviews for year end 2021. We haven't got long until we find out.....
Pmjh you're correct it's not confirmed but it's highly likely. The EMA are currently doing rolling reviews for 3 MABs with the aim of approval for October. Now they have mentioned another MAB so I think they will make up at least 3 of the 5. Now it does leave 2 others and 1 could be synairgen but feel it's a little to early even if they have access to the Activ 2 trial since it's still P2 (less than 220 patients).
Well done Doc. Good man.
That's ok. We only need one spot! ;-)